As of 2025-07-02, the Intrinsic Value of TG Therapeutics Inc (TGTX) is 16.95 USD. This TGTX valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 35.40 USD, the upside of TG Therapeutics Inc is -52.10%.
The range of the Intrinsic Value is 13.98 - 19.43 USD
Based on its market price of 35.40 USD and our intrinsic valuation, TG Therapeutics Inc (TGTX) is overvalued by 52.10%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (32.86) - (8.33) | (12.50) | -135.3% |
| DCF (Growth 10y) | (2.28) - 1.84 | (1.63) | -104.6% |
| DCF (EBITDA 5y) | 13.98 - 19.43 | 16.95 | -52.1% |
| DCF (EBITDA 10y) | 21.44 - 33.93 | 27.70 | -21.8% |
| Fair Value | 6.16 - 6.16 | 6.16 | -82.58% |
| P/E | 3.96 - 11.78 | 5.83 | -83.5% |
| EV/EBITDA | 4.30 - 24.57 | 8.85 | -75.0% |
| EPV | (3.31) - (4.49) | (3.90) | -111.0% |
| DDM - Stable | 2.83 - 16.83 | 9.83 | -72.2% |
| DDM - Multi | 3.89 - 18.35 | 6.46 | -81.8% |
| Market Cap (mil) | 5,620.10 |
| Beta | 0.78 |
| Outstanding shares (mil) | 158.76 |
| Enterprise Value (mil) | 5,732.70 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.70% |
| Cost of Debt | 9.29% |
| WACC | 7.67% |